Volume 91 Issue 26 | p. 20 | Concentrates
Issue Date: July 1, 2013

Doubt Cast On Muscle Disorder Drug Candidate’s Mechanism

Study suggests that an experimental drug to treat muscular dystrophy doesn’t work in the way scientists originally proposed
Department: Science & Technology | Collection: Life Sciences
News Channels: Biological SCENE
Keywords: ataluren, muscular dystrophy, readthrough agent

An experimental drug in human clinical trials for muscular dystrophy doesn’t work in the way scientists had originally proposed, a study finds. In 2007, PTC Therapeutics developed the small molecule ataluren as a readthrough agent, a molecule that restores protein levels in cells with mutations that block production of those proteins. In cells and in mice with a muscular dystrophy mutation, ataluren boosts levels of the disease-related protein and improves muscle function, . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society